Global Expansion BioDuro is expanding in Taiwan via a joint venture with Cenra API Solutions, adding a commercial API plant to its production network and broadening its Asia footprint to better serve global partners with regional manufacturing and supply continuity.

Integrated CRDMO The company provides fully integrated discovery through to commercial drug product manufacturing in a one-stop shop, enabling faster timelines and de-risked development for biotech and pharma partners, including IND support and specialty platforms such as bioavailability enhancement.

AI Powered Discovery BioDuro has launched an AI powered platform with Atombeat to accelerate peptide drug discovery, offering data-driven, faster hit-to-lead optimization for customers pursuing rapid early-stage development.

Global Scale With multiple global sites and a large science workforce, BioDuro presents a scalable, compliant partner capable of serving large biopharma and CRO collaborations across geographies under a unified global compliance standard.

Strategic Leadership Recent strategic moves include a 2026 acquisition by BioSelective Capital Investments and the appointment of Yaohui Ji as Global President, CMC, alongside partnerships like Cenra to strengthen Taiwan API manufacturing for global markets, signaling growth and stability for customers.